As SSTR2 PET and its associated ligands become more cost-effective and can be offered on a widespread basis, a reduction in the frequency of postoperative surveillance scans via MRI considering its limitations in predicting tumor recurrence has to be evaluated. Here, SSTR2 is linked to neoplasm.